坂井大介 (Daisuke Sakai) - マイポータル

基本情報

所属: 大阪大学

ORCID iD: https://orcid.org/0000-0002-9436-7553
J-GLOBAL ID: 202001008565179672
researchmap会員ID: R000012134

主要な論文

178

Randomized phase III study of Gemcitabine, Cisplatin plus S-1 (GCS) versus Gemcitabine, Cisplatin (GC) for Advanced Biliary Tract Cancer (KHBO1401-MITSUBA).

Tatsuya Ioka, Masashi Kanai, Shogo Kobayashi, Daisuke Sakai, Hidetoshi Eguchi, Hideo Baba, Satoru Seo, Akinobu Taketomi, Tadatoshi Takayama, Hiroki Yamaue …

Journal of hepato-biliary-pancreatic sciences 30(1) 102-110 2022年7月28日査読有り
Real-world effectiveness of third- or later-line treatment in Japanese patients with HER2-positive, unresectable, recurrent or metastatic gastric cancer: a retrospective observational study.

Daisuke Sakai, Takeshi Omori, Soichi Fumita, Junya Fujita, Ryohei Kawabata, Jin Matsuyama, Hisateru Yasui, Motohiro Hirao, Tomono Kawase, Kentaro Kishi …

International journal of clinical oncology 27(7) 1154-1163 2022年4月30日査読有り筆頭著者
A Phase II Study of Dose-reductive XELOX Plus Bevacizumab in Elderly or Vulnerable Patients With Metastatic Colorectal Cancer (MCSGO-1202).

Aya Kato, Norikatsu Miyoshi, Toru Ohtsuru, Daisuke Sakai, Junichi Hasegawa, Ken Nakata, Mitsunobu Imasato, Takeshi Kato, Masakazu Ikenaga, Toshihiro Kudo …

Anticancer research 42(4) 1859-1865 2022年4月査読有り
Clinical Utility of Next-Generation Sequencing-Based Panel Testing under the Universal Health-Care System in Japan: A Retrospective Analysis at a Single University Hospital.

Chiaki Inagaki, Daichi Maeda, Kazue Hatake, Yuki Sato, Kae Hashimoto, Daisuke Sakai, Shinichi Yachida, Norio Nonomura, Taroh Satoh

Cancers 13(5) 2021年3月5日査読有り
The initial assessment of expert panel performance in core hospitals for cancer genomic medicine in Japan

Kuniko Sunami, Yoichi Naito, Eriko Aimono, Toraji Amano, Daisuke Ennishi, Hidenori Kage, Masashi Kanai, Keigo Komine, Takafumi Koyama, Takahiro Maeda …

International Journal of Clinical Oncology 26(3) 443-449 2021年3月査読有り
Randomised phase II study of panitumumab plus irinotecan versus cetuximab plus irinotecan in patients with KRAS wild-type metastatic colorectal cancer refractory to fluoropyrimidine, irinotecan and oxaliplatin (WJOG 6510G).

Daisuke Sakai, Hiroya Taniguchi, Naotoshi Sugimoto, Takao Tamura, Tomohiro Nishina, Hiroki Hara, Taito Esaki, Tadamichi Denda, Takeshi Sakamoto, Hiroyuki Okuda …

European journal of cancer (Oxford, England : 1990) 135 11-21 2020年8月査読有り筆頭著者
Efficacy of Panitumumab and Cetuximab in Patients with Colorectal Cancer Previously Treated with Bevacizumab; a Combined Analysis of Individual Patient Data from ASPECCT and WJOG6510G.

Hiroya Taniguchi, Takeharu Yamanaka, Daisuke Sakai, Kei Muro, Kentaro Yamazaki, Susumu Nakata, Hiroyuki Kimura, Paul Ruff, Tae Won Kim, Marc Peeters …

Cancers 12(7) 2020年6月28日査読有り
Trastuzumab Deruxtecan in Previously Treated HER2-Positive Gastric Cancer.

Kohei Shitara, Yung-Jue Bang, Satoru Iwasa, Naotoshi Sugimoto, Min-Hee Ryu, Daisuke Sakai, Hyun-Cheol Chung, Hisato Kawakami, Hiroshi Yabusaki, Jeeyun Lee …

The New England journal of medicine 382(25) 2419-2430 2020年6月18日査読有り

もっとみる

MISC

ゲノム医療時代の骨・軟部腫瘍医肉腫診療におけるがんゲノム医療の実際

王谷英達, 畑毛一枝, 坂井大介, 佐藤太郎, 伊村慶紀, 中井隆彰, 名井陽, 岡田誠司

日本整形外科学会雑誌 96(6) S1284-S1284 2022年6月
COVID-19下における進行がん患者の看取りの場所の変化について

坂井大介, 長谷川晶子, 山口敏史, 大鶴徹, 武本憲彦, 佐藤太郎

日本臨床腫瘍学会学術集会(CD-ROM) 19th 2022年
A phase II study of perioperative capecitabine plus oxaliplatin for clinical SS/SE N1-3 M0 gastric cancer (OGSG1601).

Atsushi Yasuda, Jin Matsuyama, Tetsuji Terazawa, Masahiro Goto, Ryohei Kawabata, Shunji Endo, Motohiro Imano, Shoichiro Fujita, Yusuke Akamaru, Hirokazu Taniguchi …

JOURNAL OF CLINICAL ONCOLOGY 39(3) 2021年1月
レゴラフェニブで治療した進行・再発結腸直腸癌患者におけるサルコペニアの影響

村地康, 坂井大介, 小関準, 稲垣千晶, 西田尚弘, 山口敏史, 佐藤太郎

日本癌治療学会学術集会抄録集 58回 P-484 2020年10月
Wnt3a and wnt5a as potential chondrogenic stimulators for nucleus pulposus cell induction: A comprehensive review

Tibo Nico Emmie Volleman, Jordy Schol, Kosuke Morita, Daisuke Sakai, Masahiko Watanabe

Neurospine 17(1) 19-35 2020年3月1日
A phase II trial of low-dose nab-paclitaxel for patients with previously treated or recurrent advanced gastric cancer (OGSG1302)

Masashi Hirota, Shigeyuki Tamura, Hirokazu Taniguchi, Atsushi Takeno, Hiroshi Imamura, Junya Fujita, Jin Matsuyama, Yutaka Kimura, Junji Kawada, Motohiro Hirao …

JOURNAL OF CLINICAL ONCOLOGY 38(4) 2020年2月
Comparing five-weekly S-1 plus cisplatin with tri-weekly capecitabine plus cisplatin in patients with HER2-negative recurrent gastric cancer after S-1 adjuvant therapy or chemotherapy naive advanced gastric cancer: A pooled analysis of HERBIS-2 (OGSG 1103) and HERBIS-4A (OGSG 1105) trials

Jin Matsuyama, Hisato Kawakami, Kazumasa Fujitani, Yusuke Akamaru, Shigeyuki Tamura, Shunji Endo, Yutaka Kimura, Youichi Makari, Takao Tamura, Naotoshi Sugimoto …

JOURNAL OF CLINICAL ONCOLOGY 38(4) 2020年2月
人工肛門静脈瘤出血に対して、経皮経肝塞栓術を行った1例

藤本侑士, 西田尚弘, 小野祐介, 藤野志季, 荻野崇之, 坂井大介, 三吉範克, 高橋秀和, 植村守, 松田宙 …

日本癌治療学会学術集会抄録集 57回 P144-7 2019年10月
GCS療法奏効後に肝障害が出現し肝外胆管切除術にてR0を得た肝門部領域胆管癌の1例

東口公哉, 山田大作, 秋田裕史, 江口英利, 岩上佳史, 浅岡忠史, 野田剛広, 後藤邦仁, 小林省吾, 坂井大介 …

癌と化学療法 46(2) 342-344 2019年2月
Evaluation of the re-introducing FOLFOX or XELOX +/- bevacizumab in relapsed colorectal cancer patients treated with oxaliplatin as adjuvant chemotherapy (REACT study).

Shigeyoshi Iwamoto, Masahito Kotaka, Taro Ikumoto, Daisuke Sakai, Toshihiro Kudo, Akihito Tsuji, Yoshihito Ide, Mutsumi Fukunaga, Ken Konishi, Naotoshi Sugimoto …

JOURNAL OF CLINICAL ONCOLOGY 37(4) 2019年2月
Phase Ib study of andecaliximab (GS-5745, ADX) in combination with S-1+platinum chemotherapy in Japanese subjects with advanced gastric or GEJ adenocarcinoma.

Kei Muro, Taroh Satoh, Kensei Yamaguchi, Atsuo Takashima, Shigenori Kadowaki, Daisuke Sakai, Takashi Ichimura, Seiichiro Mitani, Toshihiro Kudo, Keisho Chin …

JOURNAL OF CLINICAL ONCOLOGY 37(4) 2019年2月
Phase 1b study of andecaliximab (GS-5745, ADX) as monotherapy and in combination with nivolumab (nivo) in Japanese subjects with gastric or GEJ adenocarcinoma.

Kensei Yamaguchi, Taroh Satoh, Kei Muro, Atsuo Takashima, Takashi Ichimura, Daisuke Sakai, Shigenori Kadowaki, Keisho Chin, Toshihiro Kudo, Seiichiro Mitani …

JOURNAL OF CLINICAL ONCOLOGY 37(4) 2019年2月
A dose-finding study for irinotecan, cisplatin, and S-1 (IPS) in patients with advanced gastric cancer (OGSG 1106).

Hiroki Yukami, Masahiro Goto, Takayuki Kii, Tetsuji Terazawa, Toshifumi Yamaguchi, Fukutaro Shimamoto, Hitoshi Nishitani, Hisato Kawakami, Toshio Shimokawa, Yoshihiro Matsubara …

JOURNAL OF CLINICAL ONCOLOGY 37(4) 2019年2月
An intergroup phase III trial of ramucirumab plus irinotecan in third or more line beyond progression after ramucirumab for advanced gastric cancer (RINDBeRG trial).

Daisuke Sakai, Narikazu Boku, Yasuhiro Kodera, Yoshito Komatsu, Masashi Fujii, Satoru Iwasa, Eiji Oki, Wasaburo Koizumi, Makio Gamoh, Kei Muro …

JOURNAL OF CLINICAL ONCOLOGY 36(15) 2018年5月
Analysis of RAS/BRAF mutations in a randomized phase II WJOG6510G study of panitumumab plus irinotecan versus cetuximab plus irinotecan in chemorefractory metastatic colorectal cancer.

Tomohiro Nishina, Hiroya Taniguchi, Daisuke Sakai, Hisato Kawakami, Naotoshi Sugimoto, Hiroki Hara, Taito Esaki, Tadamichi Denda, Akitaka Makiyama, Masahiro Tsuda …

JOURNAL OF CLINICAL ONCOLOGY 36(4) 2018年2月
Randomized phase II study to compare docetaxel plus S-1 with cisplatin plus S-1 in advanced gastric cancer without measurable lesions (HERBIS-3)

Jin Matsuyama, Yukinori Kurokawa, Kazuhiro Nishikawa, Yutaka Kimura, Atsushi Takeno, Junji Kawada, Ryohei Kawabata, Youichi Makari, Shigeyuki Tamura, Yuichiro Doki …

JOURNAL OF CLINICAL ONCOLOGY 36(4) 2018年2月
Randomized, open-label, phase II study comparing five-weekly S-1 plus cisplatin (SP) with tri-weekly capecitabine plus cisplatin (XP) in chemotherapy-naive patients with HER2 negative advanced gastric cancer (AGC): OGSG 1105 HERBIS-4A trial

Atsushi Takeno, Youichi Makari, Shunji Endo, Jin Matsuyama, Ryohei Kawabata, Naotoshi Sugimoto, Hirokazu Taniguchi, Kenichi Nagai, Shigeyuki Tamura, Junichi Nishijima …

JOURNAL OF CLINICAL ONCOLOGY 36(4) 2018年2月
WJOG6510G: Randomized phase II of Pmab plus IRI vs Cmab plus IRI for KRAS WT mCRC previously treated after FU, IRI, and L-OHP

Hiroki Hara, Daisuke Sakai, Toshimi Takano, Katsunori Shinozaki, Masahiro Goto, Hiroya Taniguchi, Junji Kishimoto, Narikazu Boku, Ichinosuke Hyodo, Kei Muro

ANNALS OF ONCOLOGY 28 74-74 2017年10月
Predictive value of primary tumor location: Results from randomized phase II study of panitumumab plus irinotecan versus cetuximab plus irinotecan in patients with KRAS exon2 wild-type metastatic colorectal cancer (WJOG6510G)

T. Tamura, D. Sakai, N. Sugimoto, S. Tokunaga, A. Tsuji, H. Ishida, S. Otsu, T. Moriwaki, H. Satake, K. Uchino …

ANNALS OF ONCOLOGY 28 2017年9月
Three-year outcomes of a phase II study of adjuvant chemotherapy with S-1 plus docetaxel for stage III gastric cancer after curative D2 gastrectomy (OGSG1002)

Kawabata Ryohei, Fujitani Kazumasa, Tamura Shigeyuki, Kimura Yutaka, Imamura Hiroshi, Fujita Junya, Matsuyama Jin, Iijima Shohei, Ueda Shugo, Kurokawa Yukinori …

ANNALS OF ONCOLOGY 28 2017年6月

もっとみる

共同研究・競争的資金等の研究課題

がん化学療法の精密医療の実現化

日本学術振興会科学研究費助成事業基盤研究(C) 基盤研究(C) 2018年4月 - 2021年3月

坂井大介, 石井秀始, 今野雅允
Warburg制御因子MPCによる早期脳転移機序の解明と応用

日本学術振興会科学研究費助成事業基盤研究(C) 基盤研究(C) 2018年4月 - 2021年3月

工藤敏啓, 佐藤太郎, 小関準, 坂井大介, 石井秀始
癌遺伝子選択性を実現するエピゲノム創薬の新展開

日本学術振興会科学研究費助成事業挑戦的萌芽研究挑戦的萌芽研究 2016年4月 - 2018年3月

佐藤太郎, 西田尚弘, 今野雅允, 川本弘一, 小関準, 工藤敏啓, 坂井大介, 石井秀始, 森正樹
1型糖尿病の根治を目指した新規膵β細胞誘導物質の同定と創薬展開

日本学術振興会科学研究費助成事業挑戦的萌芽研究挑戦的萌芽研究 2014年4月 - 2016年3月

坂井大介, 石井秀始, 今野雅允

坂井大介

基本情報

主要な論文

MISC

共同研究・競争的資金等の研究課題

メニュー

共著者の一覧